There are 2934 resources available
1920 - Differential expression of B7-H4, VISTA, B7-H6, HHLA2, IDO-1, PD-L1 and CD8 in EGFR mutant and wild-type lung adenocarcinoma
Presenter: Shaorong Yu
Session: Poster Discussion - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Poster Discussion - Breast cancer, metastatic - Invited Discussant 306PD and 307PD
Presenter: Aleix Prat
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Slides
Webcast
1589 - Patient-reported outcomes of palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer from the YoungPearl phase ll trial (KCSG-BR 15-10, NCT02592746)
Presenter: Soohyeon Lee
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
Poster Discussion - Breast cancer, metastatic - Invited Discussant LBA24 and 308PD
Presenter: Alexandru Eniu
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Slides
Webcast
1076 - MONARCHplus: A Phase 3 Trial of Abemaciclib plus Nonsteroidal Aromatase Inhibitor (NSAI) or Fulvestrant (F) for Women with HR+/HER2- Advanced Breast Cancer (ABC)
Presenter: Zefei Jiang
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
Poster Discussion - Breast cancer, metastatic - Invited Discussant 311PD and LBA25
Presenter: Miguel Martín
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Slides
Webcast
1911 - PIK3CA Alterations in Metastatic Breast Cancer (mBC)
Presenter: Joan Albanell
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
4351 - Emergence of ESR1 mutation in cell-free DNA during first line aromatase inhibitor and palbociclib: an exploratory analysis of the PADA-1 trial
Presenter: Francois-Clement Bidard
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
3596 - Updated overall survival (OS) and quality of life (QoL) in premenopausal patients (pts) with advanced breast cancer (ABC) who received ribociclib (RIB) or placebo (PBO) plus goserelin and a nonsteroidal aromatase inhibitor (NSAI) in the MONALEESA-7 (ML-7) trial
Presenter: Yen-Shen Lu
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract
5019 - Efficacy and Safety of First China-Manufactured Trastuzumab Biosimilar HLX02 for Metastatic Breast Cancer: A Phase 3 Trial
Presenter: Binghe Xu
Session: Poster Discussion - Breast cancer, metastatic
Resources:
Abstract